hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06328218, orgStudyIdInfo id: Gymnastics ParkinsonCommunity, briefTitle: The Effect of Simple Gymnastics Training for Parkinson's Patients in the Community, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: The goal of this clinical trial is to explore the impact of Simple Gymnastics Training on Limb motor function and mental health in Parkinson's Patients in the Community (≥60 year old) with swallowing disorders. It primarily aims to address two key aspects: 1) the prevalence of Parkinson's Diseases among community-dwelling elderly individuals, and 2) the effects of Simple Gymnastics Training on Limb motor function and mental health in community-dwelling Parkinson's Patients. All patients are required to undergo a continuous three-week (21 days) Simple Gymnastics Training, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 30 minutes each., conditionsModule conditions: Parkinson Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Simple Gymnastics Training, outcomesModule primaryOutcomes measure: Unified Parkinson's Disease Rating Scale, secondaryOutcomes measure: The Berg Balance Scale, secondaryOutcomes measure: Patient Health Questionnaire-9, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06328205, orgStudyIdInfo id: Glossopharyngeal Nerve Block, briefTitle: Impact of Glossopharyngeal Nerve Block on Swallowing Difficulties Caused by Gastroesophageal Reflux Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: The goal of this clinical trial is to explore Clinical Effect of Glossopharyngeal Nerve Block on Pharyngeal Dysphagia Induced by Gastroesophageal Reflux Disease. The main question it aims to answer is:• Can Glossopharyngeal Nerve Block improve dysphagia caused by gastroesophageal reflux symptoms on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Glossopharyngeal Nerve Block once a day additionally. The study lasts 20 days for each participant. Researchers will compare the Rosenbek penetration-aspiration scale, Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, to see if the Glossopharyngeal Nerve Block can help improve the symptom., conditionsModule conditions: Dysphagia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Rehabilitation therapy, interventions name: Glossopharyngeal Nerve Block, interventions name: Lidocaine Hydrochloride, interventions name: placebo injection, outcomesModule primaryOutcomes measure: penetration-aspiration scale, secondaryOutcomes measure: Gastroesophageal Reflux Disease Questionnaire, secondaryOutcomes measure: Pressure pain threshold, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06328192, orgStudyIdInfo id: active breathing elderly, briefTitle: The Impact of Practicing Active Breathing Exercises on Elderly Individuals Living in the Community, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Copka Sonpashan, class: OTHER_GOV, descriptionModule briefSummary: The goal of this clinical trial is to explore the impact of Active Breathing Exercises on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. It primarily aims to address two key aspects: 1) the prevalence of dysphagia among community-dwelling elderly individuals, and 2) the effects of Active Breathing Exercises on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. All participants enrolled are required to undergo a continuous three-week (21 days) Active Breathing Exercises, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 15-30 minutes each., conditionsModule conditions: Dysphagia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Active Breathing Exercises, outcomesModule primaryOutcomes measure: Standardized Swallowing Assessment Scale, secondaryOutcomes measure: Time consumed in eating, secondaryOutcomes measure: Swallowing-Related Quality of Life Questionnaire, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06328179, orgStudyIdInfo id: KY-2023-058-01, briefTitle: Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA., statusModule overallStatus: RECRUITING, startDateStruct date: 2022-05-24, primaryCompletionDateStruct date: 2027-12-30, completionDateStruct date: 2027-12-30, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Huai'an First People's Hospital, class: OTHER, collaborators name: Zhenjiang First People's Hospital, collaborators name: The First People's Hospital of Changzhou, collaborators name: The Affiliated Hospital of Xuzhou Medical University, descriptionModule briefSummary: This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities.This study includes the induction and consolidation phases of AML treatment., conditionsModule conditions: Acute Myeloid Leukemia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 34, type: ESTIMATED, armsInterventionsModule interventions name: Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；, outcomesModule primaryOutcomes measure: Overall response rate，ORR, secondaryOutcomes measure: Overall survival, OS, secondaryOutcomes measure: Event free survival, EFS, secondaryOutcomes measure: Duration of remission, DOR, otherOutcomes measure: Adverse event, AE, otherOutcomes measure: Treatment-related mortality, TRM, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University（Huai'an First People's Hospital）, status: RECRUITING, city: Huai'an, state: Jiangsu, zip: 210000, country: China, contacts name: Shandong Tao, role: CONTACT, phone: 15252393900, email: TSD8884@126.com, geoPoint lat: 33.50389, lon: 119.14417, hasResults: False
protocolSection identificationModule nctId: NCT06328166, orgStudyIdInfo id: rFGF-1 for CTS, briefTitle: The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-22, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Tri-Service General Hospital, class: OTHER, collaborators name: Eusol Biotech Co., Ltd., descriptionModule briefSummary: Carpal tunnel syndrome (CTS) is a common peripheral entrapment mononeuropathy of the upper limb, which results from compression of median nerve at level of wrist. In recent years, regenerative medicine has gradually been applied in the treatment of various degenerative conditions such as bones, muscles, and nerves. Human fibroblast growth factor 1 is a single-chain protein, which has been shown to play a crucial regulatory role in the brain and spinal cord and can facilitate nerve cell differentiation and growth. ES135 is a recombinant human fibroblast growth factor 1 (rhFGF1) which is composed of 135 amino acids with a molecular weight of approximately 15.2 kilodalton. Several studies have shown that significant improvement of Functional Independence Measure, motor and sensory function of spinal cord injury patients after ES135 treatment. One study also revealed the muscle strength have significant improvement in brachial plexus injury patients after ES135 therapy. According to above studies, the investigators hypothesized that ES135 may have benefits to CTS patients. Hence, the purpose of this study aim to demonstrate the therapeutic effects and safety of ES135 for CTS., conditionsModule conditions: Carpal Tunnel Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: Sono-guided injection with ES135, interventions name: Sono-guided injection with placebo, outcomesModule primaryOutcomes measure: Change from baseline of severity of symptoms and functional status on 1st month, 2nd month, 3rd month,4th month, 6th month after injection., secondaryOutcomes measure: Change from baseline of pain on 1st month, 2nd month, 3rd month,4th month, 6th month after injection., secondaryOutcomes measure: Change from baseline of cross-sectional area of the median nerve on 1st month, 2nd month, 3rd month,4th month, 6th month after injection., secondaryOutcomes measure: Change from baseline of conduction velocity, latency of median nerve on 1st month, 2nd month, 3rd month,4th month, 6th month., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06328114, orgStudyIdInfo id: Pro00114549, briefTitle: Accelerating TMS for Cervical Dystonia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2029-07-01, completionDateStruct date: 2029-07-01, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Duke University, class: OTHER, collaborators name: American Academy of Neurology, descriptionModule briefSummary: This study aims to investigate the impact of accelerated transcranial magnetic stimulation (TMS) on brain function and behavior in patients with focal cervical dystonia. Previous research demonstrated that individualized TMS improved writing behavior in focal hand dystonia after one session. In this study, we aim to expand the application on TMS on focal cervical dystonia. The current study administers four TMS sessions in a day. The research involves 9 in-person visits. The effect of TMS will be assessed using functional MRI brain scans and behavioral measurements. The risk of TMS includes seizures; the potential risk of seizures from TMS is mitigated through careful screening, adhering to safety guidelines. The study's main benefit is enhancing dystonic behavior and deepening the understanding of brain changes caused by TMS in cervical dystonia, paving the way for further advancements in clinical therapy for this condition., conditionsModule conditions: Isolated Cervical Dystonia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Single-arm crossover study design with subjects receiving TMS at two different intensities, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: The TMS intensity delivered at each TMS visit will be masked, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Transcranial Magnetic Stimulation (TMS), outcomesModule primaryOutcomes measure: Change in Neck Angles as Measured by Neck Sensor Device, secondaryOutcomes measure: Changes in Brain Activity (bold activity) on Functional Magnetic Resonance Imaging (fMRI), secondaryOutcomes measure: Changes in Brain Activity (functional connectivity) on Functional Magnetic Resonance Imaging (fMRI), secondaryOutcomes measure: Behavioral Response After Deep Brain Stimulation (DBS), as measured by Neck Angles, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Duke University Health System, city: Durham, state: North Carolina, zip: 27705, country: United States, contacts name: Noreen Bukhari-Parlakturk, MD PhD, role: CONTACT, phone: 919-668-8248, email: movdisres@duke.edu, geoPoint lat: 35.99403, lon: -78.89862, hasResults: False
protocolSection identificationModule nctId: NCT06328101, orgStudyIdInfo id: 2023-02558, briefTitle: Autoimmune Pancreatitis, Pancreatic and Extrapancreatic cAnceR (AiPPEAR), acronym: AiPPEAR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: University Medical Center Goettingen, class: OTHER, collaborators name: University Medical Centre Maribor, collaborators name: Aalborg University Hospital, collaborators name: University Hospital Munich, collaborators name: Tartu University Hospital, collaborators name: University Hospital in Halle, descriptionModule briefSummary: The goal of this observational, retrospective study is to learn about cancer risk in autoimmune pancreatitis (AIP) patients. The main questions it aims to answer are:* Do patients with AIP have higher incidence of cancer in comparison to general population?* What is the overall prevalence of cancer in AIP patients?* What are the characteristics of AIP patients associated with the incidence of cancer?, conditionsModule conditions: Autoimmune Pancreatitis Type 1, conditions: Autoimmune Pancreatitis Type 2, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Standardized incidence ratio (SIR) of first invasive cancer, secondaryOutcomes measure: The prevalence of cancer diagnoses 12 months prior to AIP diagnosis, secondaryOutcomes measure: Risk factor associated with cancer diagnosis., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06328088, orgStudyIdInfo id: EC/12/23/2400, briefTitle: Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis: An Open Label Pilot Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-16, primaryCompletionDateStruct date: 2024-04-16, completionDateStruct date: 2024-10-16, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Sir Ganga Ram Hospital, class: OTHER, descriptionModule briefSummary: Earlier protein restriction was advocated in the treatment of HE but later this concept was refuted and increase protein intake was advocated in patients with HE. Diet in patients during an episode HE is also not known. It is advisable based on many case reports or case series that vegetable-based diet during the episode of HE is better than animal-based diet as it reduces ammonia level and other false neurotransmitters in brain and helps in early recovery of, HE . However, diet in patients who had recovered from an episode of, HE is not known and what type of protein (vegetarian or non-vegetarian) should be taken to prevent another episode of HE has never been evaluated. In India majority of the patients are vegetarian and patients with cirrhosis are malnourished and lack protein in their diet as per our previous published study, conditionsModule conditions: Hepatic Encephalopathy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Non vegetarian, outcomesModule primaryOutcomes measure: Recurrence of overt hepatic encephalopathy, secondaryOutcomes measure: Hospitalization due to any cause, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sir Ganga Ram Hospital, status: RECRUITING, city: Delhi, zip: 110060, country: India, contacts name: Praveen Sharma, MD,DM, role: CONTACT, phone: 9810365151, geoPoint lat: 28.65195, lon: 77.23149, hasResults: False
protocolSection identificationModule nctId: NCT06328062, orgStudyIdInfo id: TUH Mirogabalin TKA, briefTitle: Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-05-31, completionDateStruct date: 2025-05-31, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Thammasat University Hospital, class: OTHER, descriptionModule briefSummary: The goal of this RCT is to compare efficacy between mirogabalin and pregabalin in pain reducing after unilateral primary total knee arthroplasty.The main question\[s\] it aims to answer are:• Does mirogabalin have better pain reduction than pregabalin after unilateral primary total knee arthroplasty.Participants will randomized to mirogabalin or pregabalin group and will take the drug for 6 weeks after TKA. Researchers will compare to pregabalin group to see pain and functional outcomes after TKA., conditionsModule conditions: Pain Postoperative, conditions: Osteoarthritis, conditions: Total Knee Arthroplasty, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Mirogabalin, interventions name: Pregabalin, outcomesModule primaryOutcomes measure: Pain score, secondaryOutcomes measure: Morphine consumption, secondaryOutcomes measure: Range of motion, secondaryOutcomes measure: Knee society score, secondaryOutcomes measure: Knee injury and Osteoarthritis Outcome Score (KOOS), secondaryOutcomes measure: Sedation score, secondaryOutcomes measure: Incidence of Somnolence and dizziness, secondaryOutcomes measure: Total hospital stay, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Thammasat University Hospital, status: RECRUITING, city: Khlong Luang, state: Pathum Thani, zip: 12120, country: Thailand, contacts name: Yot Tanariyakul, M.D., role: CONTACT, phone: 6683930257, email: y.tanariyakul@gmail.com, contacts name: Yot Tanariyakul, M.D., role: PRINCIPAL_INVESTIGATOR, contacts name: Krit Boontanapibul, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 14.06467, lon: 100.64578, hasResults: False
protocolSection identificationModule nctId: NCT06328049, orgStudyIdInfo id: HSKY-033, briefTitle: A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-08-10, primaryCompletionDateStruct date: 2025-02-10, completionDateStruct date: 2025-08-10, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Taixing People's Hospital, class: OTHER, descriptionModule briefSummary: The aim of this study is to investigate the safety and efficacy of the prophylactic use of Trilaciclib in patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy, so as to provide more evidence-based medical evidence for the optimal diagnosis and treatment strategy in this population., conditionsModule conditions: NSCLC, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Trilaciclib Injection, outcomesModule primaryOutcomes measure: Incidence of febrile neutropenia (FN), secondaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events, secondaryOutcomes measure: Antibiotic Use rate, secondaryOutcomes measure: Number of medication delays, secondaryOutcomes measure: Number of chemotherapy dose reductions, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Taixing People's Hospital, status: RECRUITING, city: Taixing, state: Jiangsu, zip: 225400, country: China, contacts name: liu C yang, M.D., role: CONTACT, phone: 87656001, phoneExt: 0523, email: liuyctx@163.com, geoPoint lat: 32.16667, lon: 120.01361, hasResults: False